Table 3 Primary and key secondary efficacy end points
End points | A8G6 (n = 178) | Control (n = 340) |
|---|---|---|
Primary end point | ||
SARS-CoV-2 confirmed by RT-qPCR | ||
No. of participants (%) | 12 (6.9%) | 151 (44.4%) |
Hazard ratio (95% CI) | 0.12 (0.07–0.22) | - |
log rank P value | 3.95E-21 | - |
Days to SARS-CoV-2 confirmed | ||
Total No. of days | 41 | 392 |
Mean days to SARS-CoV-2 confirmed (days) | 3.4 | 2.6 |
P value | 0.019 | - |
Key secondary end points | ||
High viral load at SARS-CoV-2 confirmed, ORF1ab > 105 copies/ml | ||
No. of participants (%) | 5 (41.7%) | 69 (45.7%) |
P value | 1.000 | - |
High viral load at SARS-CoV-2 confirmed, N > 105 copies/ml | ||
No. of participants (%) | 5 (41.7%) | 100 (66.2%) |
P value | 0.117 | - |
SARS-CoV-2 negative conversion | ||
No. of participants (%) | 12 (100.0%) | 151 (100.0%) |
Hazard ratio (95% CI) | 0.98 (0.54–1.77) | - |
log rank P value | 0.946 | - |
Duration of SARS-CoV-2 positive (day) | ||
Total No. of days | 80 | 917 |
Mean days of SARS-CoV-2 positive duration | 6.7 | 6.3 |
P value | 0.724 | - |
